Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
31 minute read
  • Options

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights
Today, 11:39 AM
  On Wednesday, 479 stocks made new 52-week lows.

AAP

Read More
1 minute read
  • Legal
  • News

U.S. Justice Department Says United States Files Complaint Alleging That Rite Aid Dispensed Controlled Substances In Violation Of The False Claims Act And The Controlled Substances Act

By Benzinga Newsdesk
Today, 11:39 AM
-Department Of Justice

RAD

Read More
1 minute read
  • General
  • Government
  • Health Care
  • Markets
  • News
  • Penny Stocks

New York Governor, Attorney General Ask Three Pharmacy Operators’ Commitment Over Abortion Drug Access

By Vandana Singh
Today, 11:39 AM
New York government officials Governor Kathy Hochul and Attorney General Letitia James have sent a letter to CVS Health…

CVS

Read More
4 minute read
  • Biotech
  • Cryptocurrency
  • Earnings
  • FDA
  • General
  • Health Care
  • Large Cap
  • Markets
  • Media
  • Movers
  • News
  • Penny Stocks
  • Tech
  • Top Stories
  • Trading Ideas

Google Layoffs 12K Employees, Netflix’s Q4 Earnings And CEO Steps Down, FDA Rejects Eli Lilly’s Alzheimer’s Candidate: Top Stories Friday, Jan. 20

By Vandana Singh
Today, 11:39 AM
Here's a round-up of stories from around the globe and from various media outlets. Benzinga

ABB

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • Media
  • News
  • Penny Stocks

Rite Aid Starts Selling Abortion Medication From Few Pharmacies: Report

By Vandana Singh
Today, 11:39 AM
Rite Aid Corp (NYSE: RAD) plans to dispense abortion pill mifepristone in a limited number of its pharmacies and will serve customers in person or through mail delivery.

CVS

Read More
3 minute read
  • Options

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights
Today, 11:39 AM
  On Thursday, 29 stocks made new 52-week lows.

ARQQ

Read More
1 minute read
  • Markets
  • Media
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Jim Cramer Says Forget AT&T, This ‘Class Of The Field’ Communications Stock Is Better

By Lisa Levin
Today, 11:39 AM
On CNBC’s "Mad Money Lightning Round," Jim Cramer said ADMA Biologics, Inc. (NASDAQ: ADMA) is a "great spec, but it is losing money hand over fist. I think it’s very binary.

ADMA

Read More
1 minute read
  • General
  • Health Care
  • Large Cap
  • News
  • Penny Stocks

Walgreens Boots Alliance Might Be First Pharmacy To Dispense Abortion Pills, Others To Follow

By Vandana Singh
Today, 11:39 AM
Walgreens Boots Alliance Inc (NASDAQ:WBA) is reportedly the first major national pharmacy chain to say it plans to dispense…

CVS

Read More
1 minute read
  • News

CVS, Rite Aid Say They Are Reviewing Whether To Sell Abortion Pill

By Michael Horton
Today, 11:39 AM
-Dow Jones

CVS

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Large Cap
  • Legal
  • News
  • Penny Stocks

Novartis Settles Antitrust Cases Related To Generic Entry For Hypertension Drug

By Vandana Singh
Today, 11:39 AM
Novartis AG (NYSE: NVS) will pay $245 million to end antitrust litigation accusing the company of trying to delay the U.S. launch of generic versions of its Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.

CVS

Posts navigation

1 2 … 13 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service